Registered title, quoted from ClinicalTrials.gov
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC(ARMOR2501)
An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06924398, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 2
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (2 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
1)Patients diagnosed with sMPLC (according to MM/ACCP clinical criteria). Preoperative chest CT (1mm slice thickness) reveals multiple bilateral lesions, all meeting surgical criteria [≥8mm (pure ground-glass nodules (GGNs) must be >1cm) and unchanged after standard anti-inflammatory treatment].
Inclusion criterion 1
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06924398, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- 1)Patients diagnosed with sMPLC (according to MM/ACCP clinical criteria). Preoperative chest CT (1mm slice thickness) reveals multiple bilateral lesions, all meeting surgical criteria [≥8mm (pure ground-glass nodules (GGNs) must be >1cm) and unchanged after standard anti-inflammatory treatment].
2)Patients received standard anti-inflammatory treatment before surgery.
3)The primary lesion in the operated lung is staged as T1-2N0M0.
4)Patients have undergone surgical resection of one side of the lung, with pathology confirming adenocarcinoma and an EGFR-sensitive mutation (exon 19 deletion or exon 21 L858R point mutation).
5)After unilateral resection, the contralateral lung must have at least one suspected malignant residual nodule [≥8mm (pure GGNs must be >1cm) and <3cm, unchanged after standard anti-inflammatory treatment], which must be confirmed as malignant by a qualified radiologist and thoracic surgeon.
6)ECOG performance status (PS) score of 0-1.
Exclusion Criteria:
- 1)Patients with lymph node metastasis or distant metastasis.
2)Patients with severe heart, lung, liver, or kidney dysfunction who cannot tolerate surgery.
3)Patients with a history of other malignancies within five years (except effectively controlled basal cell carcinoma, cervical carcinoma in situ, ductal carcinoma in situ of the breast, papillary thyroid carcinoma, and superficial bladder tumors).
4)Patients taking medications known to prolong the QTc interval or induce ventricular tachycardia who need to continue such medications during the study period.
5)Patients with a history of interstitial lung disease (ILD) or drug-induced ILD.
6)Patients with severe gastrointestinal dysfunction, diseases, or clinical symptoms that may affect drug intake, transport, or absorption.
7)Patients with active hepatitis B, hepatitis C, or HIV infections.
8)Pregnant or lactating women or women of childbearing potential who have not taken contraceptive measures.
9)Patients with uncontrolled neurological or psychiatric disorders or mental illnesses.
10)Patients participating in other clinical trials or expected to receive other anti-tumor treatments during this trial.
11)Other conditions deemed unsuitable for the study by the investigators
Quoted from ClinicalTrials.gov, NCT06924398, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06924398, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.